

Donna Neuberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8409797/publications.pdf>

Version: 2024-02-01

334
papers

38,906
citations

5558

82
h-index

3021

188
g-index

341
all docs

341
docs citations

341
times ranked

43325
citing authors

#	ARTICLE	IF	CITATIONS
1	Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. <i>New England Journal of Medicine</i> , 2014, 371, 2488-2498.	13.9	3,474
2	An immunogenic personal neoantigen vaccine for patients with melanoma. <i>Nature</i> , 2017, 547, 217-221.	13.7	2,112
3	Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 111-121.	13.9	1,738
4	Clinical Effect of Point Mutations in Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2011, 364, 2496-2506.	13.9	1,444
5	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nature Medicine</i> , 2018, 24, 679-690.	15.2	1,224
6	Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. <i>Cell</i> , 2013, 152, 714-726.	13.5	1,202
7	Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2010, 116, 3268-3277.	0.6	1,122
8	Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. <i>Cancer Cell</i> , 2002, 1, 75-87.	7.7	1,024
9	<i>SF3B1</i> and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2011, 365, 2497-2506.	13.9	1,021
10	Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer. <i>Science</i> , 2017, 358, 1443-1448.	6.0	983
11	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. <i>Nature</i> , 2019, 565, 234-239.	13.7	956
12	Mutations driving CLL and their evolution in progression and relapse. <i>Nature</i> , 2015, 526, 525-530.	13.7	868
13	Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. <i>Blood</i> , 2005, 105, 1851-1861.	0.6	778
14	Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. <i>Blood</i> , 2015, 125, 1367-1376.	0.6	747
15	Landscape of genomic alterations in cervical carcinomas. <i>Nature</i> , 2014, 506, 371-375.	13.7	708
16	<i>PD-L1</i> and <i>PD-L2</i> Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Journal of Clinical Oncology</i> , 2016, 34, 2690-2697.	0.8	634
17	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3005-3010.	3.3	604
18	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017, 376, 536-547.	13.9	586

#	ARTICLE	IF	CITATIONS
19	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 909-918.	15.2	488
20	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. <i>Blood</i> , 2014, 124, 2705-2712.	0.6	486
21	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2009, 114, 647-650.	0.6	414
22	Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. <i>Lancet Oncology</i> , The, 2010, 11, 950-961.	5.1	377
23	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020, 26, 1549-1556.	15.2	372
24	Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. <i>Blood</i> , 2007, 109, 896-904.	0.6	362
25	Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 2691-2698.	0.8	359
26	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1598-1605.	0.8	339
27	Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2014, 26, 813-825.	7.7	323
28	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. <i>Nature Medicine</i> , 2016, 22, 792-799.	15.2	322
29	Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. <i>Blood</i> , 1993, 81, 3449-3457.	0.6	318
30	Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant. <i>Blood</i> , 1998, 91, 3671-3680.	0.6	304
31	Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	299
32	Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML. <i>Cell</i> , 2012, 151, 344-355.	13.5	294
33	Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 453-462.	0.6	286
34	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. <i>Nature Communications</i> , 2016, 7, 11589.	5.8	285
35	Postinduction Dexamethasone and Individualized Dosing of <i>Escherichia Coli</i> L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study of Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. <i>Journal of Clinical Oncology</i> , 2013, 31, 1202-1210.	0.8	274
36	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 942-950.	0.8	273

#	ARTICLE	IF	CITATIONS
37	A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. <i>Science</i> , 2019, 365, 599-604.	6.0	265
38	Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 2420-2430.	0.6	262
39	Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. <i>Journal of Clinical Investigation</i> , 2005, 115, 1797-1805.	3.9	259
40	Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. <i>Nature Medicine</i> , 2021, 27, 515-525.	15.2	248
41	Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. <i>Nature</i> , 2021, 596, 119-125.	13.7	239
42	MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 1285-1290.	3.3	235
43	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	7.7	227
44	Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. <i>Cancer Cell</i> , 2019, 36, 369-384.e13.	7.7	224
45	Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. <i>Cancer Immunology Research</i> , 2019, 7, 100-112.	1.6	220
46	The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. <i>British Journal of Haematology</i> , 2011, 152, 452-459.	1.2	216
47	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. <i>Leukemia</i> , 2019, 33, 1747-1758.	3.3	195
48	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. <i>Blood</i> , 2020, 136, 157-170.	0.6	195
49	Intravenous pegylated asparaginase versus intramuscular native <i>Escherichia coli</i> l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 1677-1690.	5.1	193
50	Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 3128-3135.	0.8	180
51	Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2012, 22, 359-372.	7.7	179
52	Biophysical determinants for cellular uptake of hydrocarbon-stapled peptide helices. <i>Nature Chemical Biology</i> , 2016, 12, 845-852.	3.9	178
53	Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2016, 30, 750-763.	7.7	173
54	Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2014, 5, 3469.	5.8	171

#	ARTICLE	IF	CITATIONS
55	Marked hyperferritinemia does not predict for HLH in the adult population. <i>Blood</i> , 2015, 125, 1548-1552.	0.6	170
56	SYK Inhibition Modulates Distinct PI3K/AKT- Dependent Survival Pathways and Cholesterol Biosynthesis in Diffuse Large B Cell Lymphomas. <i>Cancer Cell</i> , 2013, 23, 826-838.	7.7	152
57	The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. <i>Nature Communications</i> , 2017, 8, 2185.	5.8	148
58	Classical Hodgkin Lymphoma with Reduced β 2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. <i>Cancer Immunology Research</i> , 2016, 4, 910-916.	1.6	146
59	T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation. <i>Cancer Cell</i> , 2010, 18, 353-366.	7.7	141
60	Sequence-Intrinsic Mechanisms that Target AID Mutational Outcomes on Antibody Genes. <i>Cell</i> , 2015, 163, 1124-1137.	13.5	136
61	Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. <i>Blood</i> , 2015, 126, 494-499.	0.6	128
62	Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. <i>Blood</i> , 2007, 110, 1607-1611.	0.6	126
63	Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. <i>Blood</i> , 2016, 128, 1093-1100.	0.6	126
64	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. <i>JAMA Oncology</i> , 2016, 2, 518.	3.4	121
65	Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment. <i>Blood</i> , 2018, 132, 825-836.	0.6	121
66	Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. <i>Nature Genetics</i> , 2014, 46, 618-623.	9.4	117
67	Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec). <i>Journal of Thrombosis and Haemostasis</i> , 2017, 17, 1078-1085.	0.6	117
68	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. <i>Cell</i> , 2018, 173, 624-633.e8.	13.5	113
69	Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane. <i>Journal of Clinical Oncology</i> , 2008, 26, 1106-1111.	0.8	111
70	Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E μ -TCL1 CLL mouse model. <i>Blood</i> , 2015, 126, 212-221.	0.6	111
71	Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. <i>JCI Insight</i> , 2019, 4, .	2.3	110
72	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2556-2564.	3.2	109

#	ARTICLE	IF	CITATIONS
73	Two familial ALS proteins function in prevention/repair of transcription-associated DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7701-E7709.	3.3	105
74	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2011, 208, 1595-1603.	4.2	104
75	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood, 2016, 128, 2931-2940.	0.6	102
76	The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium. European Journal of Cancer, 2011, 47, 1373-1379.	1.3	99
77	Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment. Immunity, 2020, 53, 658-671.e6.	6.6	98
78	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nature Communications, 2020, 11, 2996.	5.8	98
79	Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 207-211.	2.0	97
80	Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. JCI Insight, 2017, 2, e89373.	2.3	96
81	Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell, 2021, 184, 4969-4980.e15.	13.5	94
82	Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.. Journal of Clinical Investigation, 1997, 100, 855-866.	3.9	94
83	Absence of Biallelic α TCR β Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2010, 28, 3816-3823.	0.8	93
84	A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nature Medicine, 2020, 26, 1468-1479.	15.2	87
85	Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature, 2019, 570, 474-479.	13.7	86
86	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907.	0.6	85
87	Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood, 2016, 128, 1845-1853.	0.6	83
88	LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. Cancer Cell, 2017, 32, 310-323.e5.	7.7	80
89	Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood, 2017, 129, 3379-3385.	0.6	77
90	Integrative Genomic Analysis Implicates Gain of α PIK3CA β at 3q26 and α MYC β at 8q24 in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2012, 18, 3791-3802.	3.2	76

#	ARTICLE	IF	CITATIONS
91	Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. <i>Blood</i> , 1998, 91, 3671-80.	0.6	75
92	Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. <i>Blood Advances</i> , 2018, 2, 1449-1458.	2.5	73
93	Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. <i>American Journal of Hematology</i> , 2016, 91, 322-329.	2.0	72
94	A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. <i>Cancer Cell</i> , 2019, 35, 283-296.e5.	7.7	71
95	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. <i>Cancer Cell</i> , 2019, 35, 664-676.e7.	7.7	70
96	Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. <i>Nature</i> , 2022, 605, 532-538.	13.7	70
97	Impact of Socioeconomic Status on Timing of Relapse and Overall Survival for Children Treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000-2010). <i>Pediatric Blood and Cancer</i> , 2016, 63, 1012-1018.	0.8	69
98	Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. <i>Genome Research</i> , 2017, 27, 1300-1311.	2.4	67
99	The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. <i>British Journal of Haematology</i> , 2016, 173, 105-113.	1.2	66
100	Somatic mutation as a mechanism of Wnt/ β -catenin pathway activation in CLL. <i>Blood</i> , 2014, 124, 1089-1098.	0.6	65
101	Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency. <i>Leukemia</i> , 2012, 26, 2069-2078.	3.3	64
102	Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. <i>Blood</i> , 2014, 123, 4101-4110.	0.6	63
103	NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. <i>Leukemia</i> , 2013, 27, 2077-2081.	3.3	57
104	Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 2205-2211.	0.8	57
105	Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 1252-1257.	0.8	57
106	Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. <i>American Journal of Hematology</i> , 2019, 94, 446-454.	2.0	56
107	CDK6 Antagonizes p53-Induced Responses during Tumorigenesis. <i>Cancer Discovery</i> , 2018, 8, 884-897.	7.7	53
108	Polymorphisms of Asparaginase Pathway and Asparaginase-Related Complications in Children with Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 329-334.	3.2	52

#	ARTICLE	IF	CITATIONS
109	Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment. <i>Nature Cancer</i> , 2021, 2, 758-772.	5.7	52
110	Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. <i>Blood</i> , 1994, 84, 3974-3979.	0.6	51
111	Emergence, Involution, and Progression to Carcinoma of Mutant Clones in Normal Endometrial Tissues. <i>Cancer Research</i> , 2014, 74, 2796-2802.	0.4	48
112	Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. <i>Leukemia</i> , 2015, 29, 1555-1563.	3.3	48
113	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018, 32, 2126-2137.	3.3	48
114	Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27062.	0.8	48
115	Pattern of Frequent But Nontargeted Pharmacologic Thromboprophylaxis for Hospitalized Patients With Cancer at Academic Medical Centers: A Prospective, Cross-Sectional, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1792-1796.	0.8	45
116	Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBP β expression. <i>Science Translational Medicine</i> , 2016, 8, 350ra104.	5.8	45
117	A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. <i>Blood</i> , 2018, 132, 1911-1921.	0.6	44
118	Microbial symbionts regulate the primary Ig repertoire. <i>Journal of Experimental Medicine</i> , 2018, 215, 1397-1415.	4.2	43
119	Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8614-8619.	3.3	42
120	Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. <i>Science Immunology</i> , 2022, 7, eabp8328.	5.6	40
121	Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. <i>JCI Insight</i> , 2018, 3, .	2.3	39
122	Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. <i>Blood Advances</i> , 2017, 1, 1645-1649.	2.5	38
123	A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial. <i>Blood</i> , 2015, 126, 80-80.	0.6	38
124	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 3094-3114.	4.2	37
125	Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. <i>Cell Reports</i> , 2021, 37, 109992.	2.9	37
126	Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 3336-3342.	0.6	36

#	ARTICLE	IF	CITATIONS
127	Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. <i>Blood</i> , 2018, 132, 170-178.	0.6	36
128	Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. <i>Journal of Clinical Oncology</i> , 2021, 39, 3496-3505.	0.8	36
129	Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. <i>Clinical Cancer Research</i> , 2015, 21, 3178-3186.	3.2	34
130	A strategy to improve treatment-related mortality and abandonment of therapy for childhood ALL in a developing country reveals the impact of treatment delays. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1395-1402.	0.8	34
131	Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. <i>Cancer</i> , 2016, 122, 946-953.	2.0	34
132	Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. <i>Haematologica</i> , 2017, 102, 498-508.	1.7	34
133	Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. <i>Blood Advances</i> , 2018, 2, 529-533.	2.5	34
134	Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 719-727.	1.7	33
135	Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients. <i>Oncotarget</i> , 2017, 8, 43752-43767.	0.8	33
136	Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma. <i>Blood</i> , 2016, 128, 4052-4052.	0.6	32
137	Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. <i>Modern Pathology</i> , 2015, 28, 965-976.	2.9	31
138	The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 306-314.	1.0	31
139	Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26952.	0.8	31
140	Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. <i>Cancer Discovery</i> , 2021, 11, 3048-3063.	7.7	31
141	A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 3867-3867.	0.6	30
142	MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice. <i>American Journal of Clinical Pathology</i> , 2016, 145, 166-179.	0.4	29
143	A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. <i>Cancer Cell</i> , 2021, 39, 380-393.e8.	7.7	27
144	The clinical and functional effects of TERT variants in myelodysplastic syndrome. <i>Blood</i> , 2021, 138, 898-911.	0.6	27

#	ARTICLE	IF	CITATIONS
145	Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. <i>Oncotarget</i> , 2017, 8, 67639-67650.	0.8	26
146	Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00â€‘001 and 05â€‘001. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27256.	0.8	26
147	Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05â€‘001 and 11â€‘001. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28719.	0.8	26
148	Genomic profiling of a randomized trial of interferon-Î± vs hydroxyurea in MPN reveals mutation-specific responses. <i>Blood Advances</i> , 2022, 6, 2107-2119.	2.5	26
149	Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy Specimens. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 19-30.	1.2	25
150	Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. <i>Blood</i> , 2020, 136, 3070-3081.	0.6	25
151	Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1449-1451.	1.9	24
152	A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2014, 38, 430-434.	0.4	23
153	Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. <i>Cancer</i> , 2018, 124, 306-314.	2.0	23
154	An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05â€‘001. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26871.	0.8	23
155	CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. <i>Haematologica</i> , 2020, 105, 1361-1368.	1.7	23
156	Amino acid-insensitive mTORC1 regulation enables nutritional stress resilience in hematopoietic stem cells. <i>Journal of Clinical Investigation</i> , 2017, 127, 1405-1413.	3.9	23
157	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 1929-1945.	4.2	22
158	Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. <i>Blood Advances</i> , 2020, 4, 2254-2260.	2.5	22
159	Clonal Evolution In Patients With Chronic Lymphocytic Leukemia (CLL) Developing Resistance To BTK Inhibition. <i>Blood</i> , 2013, 122, 866-866.	0.6	22
160	PPARÎ³ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF. <i>Cancer Immunology Research</i> , 2018, 6, 723-732.	1.6	21
161	Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy. <i>Scientific Reports</i> , 2020, 10, 723.	1.6	21
162	Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea. <i>Blood</i> , 2015, 125, 3668-3669.	0.6	20

#	ARTICLE	IF	CITATIONS
163	Association of mutations with morphological dysplasia in <i>de novo</i> acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. <i>Haematologica</i> , 2018, 103, 626-633.	1.7	20
164	Controversial fluorescence <i>in situ</i> hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. <i>British Journal of Haematology</i> , 2015, 170, 694-703.	1.2	19
165	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e122-e133.	2.2	19
166	The Impact of Age and Sex in DLBCL: Systems Biology Analyses Identify Distinct Molecular Changes and Signaling Networks. <i>Cancer Informatics</i> , 2015, 14, CIN.S34144.	0.9	18
167	Plateletpheresis-associated lymphopenia in frequent platelet donors. <i>Blood</i> , 2019, 133, 605-614.	0.6	17
168	Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	17
169	<i>ZBTB33</i> Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing. <i>Blood Cancer Discovery</i> , 2021, 2, 500-517.	2.6	17
170	Loss of function <i>tp53</i> mutations do not accelerate the onset of <i>myc</i> -induced T-cell acute lymphoblastic leukaemia in the zebrafish. <i>British Journal of Haematology</i> , 2014, 166, 84-90.	1.2	16
171	Influence of BCL2L11 polymorphism on osteonecrosis during treatment of childhood acute lymphoblastic leukemia. <i>Pharmacogenomics Journal</i> , 2019, 19, 33-41.	0.9	16
172	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 54-69.	2.6	16
173	Mitochondrial Variations in Non-Small Cell Lung Cancer (NSCLC) Survival. <i>Cancer Informatics</i> , 2015, 14s1, CIN.S13976.	0.9	15
174	Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 2651-2663.	0.6	15
175	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 5395.	5.8	15
176	Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. <i>American Journal of Hematology</i> , 2016, 91, 793-799.	2.0	14
177	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. <i>Blood</i> , 2018, 132, 228-228.	0.6	14
178	Dexamethasone and Individualized Asparaginase Dosing Are Each Associated with Superior Event-Free Survival in Childhood Acute Lymphoblastic Leukemia: Results From DFCI-ALL Consortium Protocol 00-01. <i>Blood</i> , 2009, 114, 321-321.	0.6	14
179	Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial. <i>Blood</i> , 2013, 122, 3062-3062.	0.6	14
180	Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 860-865.	1.0	13

#	ARTICLE	IF	CITATIONS
181	Intensified Chemotherapy Regimen for Very High Risk Childhood B-Precursor Acute Lymphoblastic Leukemia (B-ALL): Results From Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 05â€“01. <i>Blood</i> , 2012, 120, 3563-3563.	0.6	13
182	Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients. <i>Blood Cancer Journal</i> , 2021, 11, 176.	2.8	13
183	Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3356-3366.	3.2	13
184	<i>NPM1</i> mutation but not <i>RUNX1</i> mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification. <i>American Journal of Hematology</i> , 2017, 92, E123-E124.	2.0	11
185	Randomized Study of Pegaspargase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001. <i>Blood</i> , 2016, 128, 175-175.	0.6	11
186	Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 632-638.	0.7	10
187	Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3741-E3748.	3.3	10
188	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. <i>Clinical Cancer Research</i> , 2021, 27, 5072-5083.	3.2	10
189	Activation of <i>Notch</i> and <i>Myc</i> Signaling via B-cellâ€“Restricted Depletion of <i>Dnmt3a</i> Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2021, 81, 6117-6130.	0.4	10
190	Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	10
191	Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease. <i>PLoS ONE</i> , 2019, 14, e0218783.	1.1	9
192	HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium. <i>Pharmacogenomics</i> , 2020, 21, 541-547.	0.6	9
193	Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 766-766.	0.6	9
194	Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. <i>Clinical Cancer Research</i> , 2017, 23, 4680-4692.	3.2	8
195	Overall survival with warfarin vs. lowâ€“molecularâ€“weight heparin in cancerâ€“associated thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2825-2834.	1.9	8
196	Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE). <i>Blood</i> , 2015, 126, 543-543.	0.6	8
197	Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients. <i>Pharmacogenomics</i> , 2019, 20, 1189-1197.	0.6	7
198	CD4+ Tâ€“cell lymphopenia in frequent platelet donors who have ceased platelet donation for at least 1 year. <i>Transfusion</i> , 2019, 59, 1644-1647.	0.8	7

#	ARTICLE	IF	CITATIONS
199	Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2688-2692.	3.3	7
200	Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma: Results of DFCI 11-001.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10006-10006.	0.8	7
201	Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. <i>Blood</i> , 1993, 81, 3449-3457.	0.6	7
202	Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. <i>Blood</i> , 2022, 139, 2252-2256.	0.6	7
203	Using recursive partitioning for exploration and follow-up of linkage and association analyses. <i>Genetic Epidemiology</i> , 1999, 17, S391-6.	0.6	6
204	Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. <i>Blood Advances</i> , 2016, 1, 84-92.	2.5	6
205	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018, 132, 749-749.	0.6	6
206	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. <i>Blood</i> , 2019, 134, 4172-4172.	0.6	6
207	Randomized Comparison of IV PEG and IM E. Coli Asparaginase in Children and Adolescents with Acute Lymphoblastic Leukemia: Results of the DFCI ALL Consortium Protocol 05-01. <i>Blood</i> , 2011, 118, 874-874.	0.6	6
208	Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 249-249.	0.6	6
209	Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2597-2597.	0.6	6
210	Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma.. <i>Blood</i> , 2007, 110, 2331-2331.	0.6	6
211	Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29581.	0.8	6
212	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. <i>Clinical Cancer Research</i> , 2021, 27, 5049-5061.	3.2	6
213	Dynamic changes in $\text{CCL}3$ and $\text{CCL}4$ plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. <i>British Journal of Haematology</i> , 2018, 180, 597-600.	1.2	5
214	Severe CD4+ T-cell lymphopenia is not observed in frequent plateletpheresis donors collected on the Fenwal Amicus. <i>Transfusion</i> , 2019, 59, 2783-2787.	0.8	5
215	Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium. <i>Blood</i> , 2011, 118, 291-291.	0.6	5
216	Higher Incidence of Treatment-Related Toxicities in Non-Hispanic Patients Undergoing Therapy for Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001. <i>Blood</i> , 2015, 126, 248-248.	0.6	5

#	ARTICLE	IF	CITATIONS
217	Chromosome 9p24.1/PD-L1/PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). <i>Blood</i> , 2016, 128, 2923-2923.	0.6	5
218	Genetic Determinants of Venetoclax Resistance in Lymphoid Malignancies. <i>Blood</i> , 2018, 132, 893-893.	0.6	4
219	Addition of Bortezomib (Velcade) to AML Induction Chemotherapy Is Well Tolerated and Results in a High Complete Remission Rate.. <i>Blood</i> , 2005, 106, 2782-2782.	0.6	4
220	Large Regions of Uniparental Disomy (UPD) Establish Clonal Hematopoietic Stem Cell Selection in a Subset of Myelodysplastic Syndrome (MDS) Patients with Normal Bone Marrow Cell Karyotypes.. <i>Blood</i> , 2007, 110, 120-120.	0.6	4
221	Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease. <i>Blood</i> , 2015, 126, 2613-2613.	0.6	4
222	Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy. <i>Blood</i> , 2015, 126, 362-362.	0.6	4
223	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Blood</i> , 2015, 126, 176-176.	0.6	4
224	Telomere Length and Telomerase Complex Mutations Predict Fatal Treatment Toxicity after Stem Cell Transplantation in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 796-796.	0.6	3
225	Obatoclox in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL. <i>Blood</i> , 2011, 118, 2865-2865.	0.6	3
226	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 311-311.	0.6	3
227	Homozygosity for the 2R Tandem Repeat Polymorphism in the Thymidylate Synthase (TS) Promoter Is Associated with Increased Risk for Bony Morbidity Among Children Treated for Acute Lymphoblastic Leukemia on DFCI Protocol 05-001. <i>Blood</i> , 2015, 126, 251-251.	0.6	3
228	Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 3765-3765.	0.6	3
229	The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL. <i>Blood</i> , 2016, 128, 188-188.	0.6	3
230	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 986-986.	0.6	3
231	MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers. <i>Blood</i> , 2019, 134, 1284-1284.	0.6	3
232	Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study. <i>Blood</i> , 2019, 134, 2015-2015.	0.6	3
233	High Incidence of Bleeding Found with Direct Oral Anticoagulant Use in Myeloproliferative Neoplasm Patients. <i>Blood</i> , 2021, 138, 3632-3632.	0.6	3
234	Antiplatelet medications and risk of intracranial hemorrhage in patients with metastatic brain tumors. <i>Blood Advances</i> , 2022, 6, 1559-1565.	2.5	3

#	ARTICLE	IF	CITATIONS
235	Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients. <i>Leukemia</i> , 2022, 36, 1176-1179.	3.3	3
236	Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study. <i>PLoS Medicine</i> , 2022, 19, e1004012.	3.9	3
237	Postoperative bridging anticoagulation and left ventricular assist system thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 57-66.	1.0	2
238	A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. , 0, .		2
239	A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 1654-1654.	0.6	2
240	Interrogation of Individual CLL Loss-of-Function Lesions By CRISPR In Vivo Editing Reveals Common and Unique Pathway Alterations. <i>Blood</i> , 2019, 134, 684-684.	0.6	2
241	A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.. <i>Blood</i> , 2007, 110, 1358-1358.	0.6	2
242	Increased Risk of Skeletal Toxicity and Infection in Children 10 Years or Older Treated for Acute Lymphoblastic Leukemia (ALL) with Dexamethasone: Results from the DFCI ALL Consortium.. <i>Blood</i> , 2007, 110, 849-849.	0.6	2
243	Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 306-306.	0.6	2
244	Genetic Alterations Predict Outcomes in Patients with Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 69-69.	0.6	2
245	Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5010-5010.	0.8	2
246	Pharmacodynamics and Tolerability of Twice-Weekly Erwinia Asparaginase after E. coli Asparaginase Allergy in Children with ALL.. <i>Blood</i> , 2006, 108, 1857-1857.	0.6	2
247	Comprehensive Bulk and Single Cell Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2906-2906.	0.6	2
248	The End of Life for Patients with Acute Myeloid Leukemia (AML)- a Single Center Experience. <i>Blood</i> , 2015, 126, 3318-3318.	0.6	2
249	A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 5218-5218.	0.6	2
250	How many mice? Design considerations for murine studies. <i>Blood Advances</i> , 2017, 1, 1466-1466.	2.5	1
251	Statistics Everywhere. <i>HemaSphere</i> , 2018, 2, e30.	1.2	1
252	Pretreatment clinical and genetic factors predict early post-treatment mortality in fit <sc>AML</sc> patients following induction. <i>American Journal of Hematology</i> , 2021, 96, E259-E262.	2.0	1

#	ARTICLE	IF	CITATIONS
253	Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response. <i>Blood</i> , 2019, 134, 4202-4202.	0.6	1
254	HOXB9 Is Aberrantly Expressed in Blast Cells in a Subset of Acute Myeloid Leukemia Patients and Supports Proliferation of AML Cell Lines. <i>Blood</i> , 2005, 106, 1613-1613.	0.6	1
255	The Frequency and Management of Asparaginase-Related Thrombosis in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Treated On the Dana-Farber Cancer Institute (DFCI) Consortium Protocols.. <i>Blood</i> , 2009, 114, 3073-3073.	0.6	1
256	Shifts in Intra-Clonal Dynamics Rather Than Novel Mutations Are the Main Engine Driving Tumor Evolution in Relapsed CLL. <i>Blood</i> , 2011, 118, 284-284.	0.6	1
257	A Comparative Retrospective Survey of Reinduction Chemotherapy Regimens for Acute Myeloid Leukemia (AML) in First Relapse: A Single-Institution Experience. <i>Blood</i> , 2011, 118, 4273-4273.	0.6	1
258	Retrospective Analysis of Thrombocytopenia in Relapsed Multiple Myeloma Patients. <i>Blood</i> , 2011, 118, 5073-5073.	0.6	1
259	Comparison of Minimal Residual Disease Detection Using High-Throughput Sequencing and Allele-Specific Oligonucleotide PCR Methods in Pediatric B-Lineage Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2012, 120, 2532-2532.	0.6	1
260	Risk Alleles Identified in Genome-Wide Association Studies Are Associated with Expression Quantitative Trait Loci in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2875-2875.	0.6	1
261	Reconstructing a Genotype-Phenotype Map In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 2857-2857.	0.6	1
262	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1713-1713.	0.6	1
263	Expression of Sf3b1- K700E in Murine B Cells Causes Pre-mRNA Splicing and Altered B Cell Differentiation and Function. <i>Blood</i> , 2015, 126, 366-366.	0.6	1
264	Intracranial Hemorrhage in Patients with Primary Brain Tumors Treated with Therapeutic Enoxaparin: A Matched Cohort Study. <i>Blood</i> , 2016, 128, 142-142.	0.6	1
265	PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 604-604.	0.6	1
266	MDM2 polymorphism and recurrence-free and overall survival in early stage non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2006, 24, 7221-7221.	0.8	1
267	CIMAC-CIDC tissue imaging harmonization.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3125-3125.	0.8	1
268	Expression of T Cell Co-Stimulator (ICOS) and Its Ligand and Disease Progression in B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2005, 106, 2943-2943.	0.6	1
269	Intravenous PEG Asparaginase during Remission Induction for Childhood ALL.. <i>Blood</i> , 2006, 108, 1854-1854.	0.6	1
270	TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 1470-1470.	0.6	1

#	ARTICLE	IF	CITATIONS
271	Single Cell Transcriptomic Characterization of the Immune Microenvironment in Naturally Progressing Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 3112-3112.	0.6	1
272	T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation. <i>Blood</i> , 2019, 134, 680-680.	0.6	1
273	Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies. <i>Blood</i> , 2019, 134, 2549-2549.	0.6	1
274	Reply to comment on: Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27082.	0.8	0
275	Wrangling with \hat{P} -values. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26834.	0.8	0
276	Reply to Z. Wu et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2657-2657.	0.8	0
277	Testing for clonal hematopoiesis of indeterminate potential in breast cancer survivors.. <i>Journal of Clinical Oncology</i> , 2021, 39, e24108-e24108.	0.8	0
278	The $ERCC1\ C8092A$ polymorphism and grade III/IV gastrointestinal (GI) toxicity in non-small cell lung cancer (NSCLC) patients treated with chemoradiation. <i>Journal of Clinical Oncology</i> , 2004, 22, 2014-2014.	0.8	0
279	Inhibiting TNF \pm with etanercept in relapsed/refractory follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 17525-17525.	0.8	0
280	Emi1 Is Required for Normal Cell Cycle Progression in Zebrafish Myelopoiesis and Likely Functions as a Haploinsufficient Tumor Suppressor on Chromosome 6q in Human Leukemias.. <i>Blood</i> , 2006, 108, 1405-1405.	0.6	0
281	Engineered Expression of JAK2V617F Drastically Changes the Response of Progenitor Cells to Erythropoietin and Partially Mimics the Polycythemia Expression Signature.. <i>Blood</i> , 2006, 108, 3597-3597.	0.6	0
282	Bcl2 Accelerates Onset but Not Progression of MYC-Induced T-Cell Leukemia in Transgenic Zebrafish.. <i>Blood</i> , 2006, 108, 1829-1829.	0.6	0
283	Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse.. <i>Blood</i> , 2006, 108, 3041-3041.	0.6	0
284	Novel Germline Genetic Variants Associated with Familial Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2011, 118, 465-465.	0.6	0
285	Regadenoson, An Adenosine 2A Receptor Agonist, Is Safe and Inhibits Invariant NKT Cells in Sickle Cell Disease. <i>Blood</i> , 2011, 118, 849-849.	0.6	0
286	Treatment of Chronic Lymphocytic Leukemia Patients with Lenalidomide Induces Down-Regulation of miR342-3p Associated with Over-Expression of Tumor Suppressor RASSF4,. <i>Blood</i> , 2011, 118, 3885-3885.	0.6	0
287	Large-Scale CLL Genome Analysis Reveals Novel Cancer Genes, Including SF3B1. <i>Blood</i> , 2011, 118, 463-463.	0.6	0
288	MicroRNA Profiling in Patients with CLL B Cells Expressing the Unmutated IGHV1-69 Gene. <i>Blood</i> , 2011, 118, 2846-2846.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Rearrangement of 14q32 in the Absence of t(14;18) Is Associated with Short Time to First Treatment in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 1438-1438.	0.6	0
290	Clinical Significance of Coagulation Studies in Predicting Response to Recombinant Factor VIIa in Cardiac Surgery Patients. <i>Blood</i> , 2011, 118, 4351-4351.	0.6	0
291	Somatic Mutation As a Mechanism of Wnt/ β^2 -Catenin Pathway Activation in CLL. <i>Blood</i> , 2012, 120, 559-559.	0.6	0
292	Systematic Identification of Personal Mutated Tumor-Specific Neoantigens in CLL. <i>Blood</i> , 2012, 120, 954-954.	0.6	0
293	Association of Baseline Body Mass Index (BMI) with Overall Survival Among Patients Over Age 60 with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2012, 120, 1484-1484.	0.6	0
294	A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1534-1534.	0.6	0
295	Galectin-1 Serum Levels Reflect Tumor Burden and Adverse Clinical Features in Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 51-51.	0.6	0
296	Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2012, 120, 1700-1700.	0.6	0
297	The Impact of Insurance Status at Diagnosis on Overall Survival in Chronic Myeloid Leukemia: A Population-Based Analysis. <i>Blood</i> , 2015, 126, 631-631.	0.6	0
298	Comparison of Age at Diagnosis, Cytogenetic Risk, and Overall Survival Between Acute Myeloid Leukemia Patients of White and South Asian Race/Ethnicity in the United States. <i>Blood</i> , 2015, 126, 3753-3753.	0.6	0
299	Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3922-3922.	0.6	0
300	Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets. <i>Blood</i> , 2015, 126, 2655-2655.	0.6	0
301	Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center. <i>Blood</i> , 2015, 126, 1304-1304.	0.6	0
302	The Impact of Age and Sex in DLBCL: Determination of Biologic Dynamics and Delineation of Inter-Connected Signaling Networks Via a Systems Biology Analysis. <i>Blood</i> , 2015, 126, 2672-2672.	0.6	0
303	Post-Operative Anticoagulation and the Incidence of Left Ventricular Assist Device Thrombosis. <i>Blood</i> , 2016, 128, 2620-2620.	0.6	0
304	The Impact of Regional Cardiovascular Care Outcomes on Survival and Cardiovascular-Specific Mortality in Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 5984-5984.	0.6	0
305	Progression in Patients with with Low- and Intermediate-1 Risk Del(5q) MDS Is Predicted By a Limited Subset of Mutations. <i>Blood</i> , 2016, 128, 4329-4329.	0.6	0
306	Genome-Wide Analysis of a Novel Murine Model of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 967-967.	0.6	0

#	ARTICLE	IF	CITATIONS
307	Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001. <i>Blood</i> , 2016, 128, 761-761.	0.6	0
308	PDI Inhibition Blocks Thrombin Generation in Humans By Interfering with Platelet Factor V Activation. <i>Blood</i> , 2016, 128, 2628-2628.	0.6	0
309	Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium. <i>Blood</i> , 2016, 128, 1729-1729.	0.6	0
310	Fetal Erythropoiesis Is Defective in Rpl11 Heterozygous Mice and Increases in Severity in Young Animals. <i>Blood</i> , 2017, 130, 872-872.	0.6	0
311	The Benefits of TRTHing along. <i>HemaSphere</i> , 2018, 2, e138.	1.2	0
312	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. <i>Blood</i> , 2018, 132, 891-891.	0.6	0
313	Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults. <i>Blood</i> , 2018, 132, 2704-2704.	0.6	0
314	Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study). <i>Blood</i> , 2018, 132, 985-985.	0.6	0
315	Sudden Death in Sickle Cell Disease: An Assessment of Risk Factors. <i>Blood</i> , 2018, 132, 4929-4929.	0.6	0
316	Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults. <i>Blood</i> , 2018, 132, 4059-4059.	0.6	0
317	CD4+ T-Cell Lymphopenia in Frequent Platelet Donors Who Have Ceased Platelet Donation for at Least 1 Year. <i>Blood</i> , 2018, 132, 2550-2550.	0.6	0
318	Safety of Direct-Acting Oral Anticoagulants Versus Enoxaparin in Patients with Primary and Metastatic Brain Tumors. <i>Blood</i> , 2018, 132, 2521-2521.	0.6	0
319	KZF-L162R Mutation Affects Splenic Mature B Cell Development and Alters Expression of Aiolos Target Genes. <i>Blood</i> , 2018, 132, 668-668.	0.6	0
320	Mapping the Evolution of T Cell Transcriptional States during DLI Response and Resistance Using Single-Cell Data. <i>Blood</i> , 2018, 132, 821-821.	0.6	0
321	Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 820-820.	0.6	0
322	Potential Barriers to Clinical Trials of New Therapeutics for Myelodysplastic Syndromes: Wide Variation in Risk Definitions and Trial Enrollment Criteria. <i>Blood</i> , 2018, 132, 4378-4378.	0.6	0
323	Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1431-1431.	0.6	0
324	PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL. <i>Blood</i> , 2018, 132, 889-889.	0.6	0

#	ARTICLE	IF	CITATIONS
325	B Cell Restricted Expression of Mutated IKZF3 modulates BCR Signaling and Homing Pathways in a Mouse Model of CLL. <i>Blood</i> , 2019, 134, 848-848.	0.6	0
326	Lineage Tracing in Chronic Lymphocytic Leukemia Reveals Clones with Stable Gene Expression States That Differentially Respond to Therapy. <i>Blood</i> , 2019, 134, 1229-1229.	0.6	0
327	Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL. <i>Blood</i> , 2019, 134, 4281-4281.	0.6	0
328	Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL). <i>Blood</i> , 2019, 134, 516-516.	0.6	0
329	Inducible Phase Separation of GSK3 β As a Mechanism for Asparaginase Resistance in Acute Leukemias. <i>Blood</i> , 2019, 134, 169-169.	0.6	0
330	Recurrent Intracranial Hemorrhage and Venous Thromboembolism Following Initial Intracranial Hemorrhage in Patients with Brain Tumors on Anticoagulation. <i>Blood</i> , 2019, 134, 2438-2438.	0.6	0
331	Deciphering the Role of Locally Disordered DNA Methylation on CLL Development In Vivo. <i>Blood</i> , 2019, 134, 1737-1737.	0.6	0
332	A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503. <i>Blood</i> , 2019, 134, 4592-4592.	0.6	0
333	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. <i>Clinical Cancer Research</i> , 2021, 27, 5049-5061.	3.2	0
334	The ERCC1 C8092A polymorphism and grade III/IV gastrointestinal (GI) toxicity in non-small cell lung cancer (NSCLC) patients treated with chemoradiation. <i>Journal of Clinical Oncology</i> , 2004, 22, 2014-2014.	0.8	0